Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics
Year: 2020
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Treatment resistant depression (TRD; failure to respond to ≥2 treatments) affects ~20% of patients with major depressive disorder (MDD). Real-world data could help describe patient characteristics and TRD disease burden, to assess the unmet needs of TRD patients in Europe. METHODS: This observational study collected data from adults with moderate to severe TRD initiating a new treatment for depression, according to local standards of care. At baseline, socio-demographic characteristics, medical history, prior and current treatments were recorded. Disease severity, health-related quality of life (HRQoL), functionality and productivity were assessed. RESULTS: Overall, 411 eligible patients were enrolled across seven European countries. Mean (standard deviation [SD]) patient age was 51.0 (10.8) years; 62.3% were female. Long-term sick leave was reported by 19.0% of patients; 30.2% were unemployed. The mean (SD) duration of the current episode was 2.6 (3.9) years. At baseline, mean (SD) HRQoL scores for EuroQoL 5-dimension 5-level (UK tariff) and EQ-Visual Analog Scale were 0.41 (0.25) and 41.1 (18.7), respectively. The Work Productivity and Activity Impairment questionnaire demonstrated mean (SD) absenteeism of 57.0% (44.9%) and presenteeism of 54.7% (29.5%); mean (SD) overall work impairment was 60.5% (29.9%). LIMITATIONS: Key limitations are small cohort size, absence of a control group and generalizability to countries with different healthcare models. CONCLUSIONS: TRD patients had a high disease burden, low HRQoL and reduced function and productivity, with a substantial proportion unable to work. This demonstrates an unmet treatment need in TRD patients that, if addressed, could reduce the heavy personal and societal burden.
Source: Journal of Affective Disorders
Institutions: Janssen (Germany), National Health Service, King's College London, South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Charité – Universitätsmedizin Berlin, University Hospital Magdeburg, Otto-von-Guericke-Universität Magdeburg, Alma, Universidade Nova de Lisboa, Universitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, Hospital Del Mar, Municipal Institute for Medical Research, Hospital del Mar Research Institute, Southern Health NHS Foundation Trust, University of Turin, Universitat de València, Hospital Universitari i Politècnic La Fe, Janssen (Belgium), University of Pisa
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,350
Funders: Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, South London and Maudsley NHS Foundation Trust, Sunovion, LivaNova, Sage Therapeutics, National Institute for Health and Care Research, King's College London, European Commission, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Ministerio de Economía y Competitividad, Centro de Investigación Biomédica en Red de Salud Mental, Servier, H. Lundbeck A/S, Neuraxpharm, Schuhfried, Allergan, Horizon 2020 Framework Programme, Fundação para a Ciência e a Tecnologia, Cilag
Awards: G1178615512, G1516346500, G2120957160, a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment, G36204382, G434337789, Flexibilidade cognitiva, excitabilidade cortical e efeito antidepressivo da psilocibina, G4937468798, Predicting Effective Adaptation to Breast Cancer to Help Women to BOUNCE Back, G5454278309, G5617471882, G6049260834, G6516029681, G8490170426, NIHR Senior Investigator Award
OpenAlex ID: W3109964933
